Advanced Filters
noise

PARIS cedex 14, France Clinical Trials

A listing of PARIS cedex 14, France clinical trials actively recruiting patients volunteers.

Found 1,555 clinical trials
G Georgina Hall

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.

years of age All Phase N/A

MPS (RaDiCo Cohort) (RaDiCo-MPS)

The goal of this observational study is to characterize the epidemiology and natural history of MPS diseases by building a retrospective and prospective collection of extensive phenotypic data from French MPS patients.

years of age All Phase N/A
J Jean-Philippe Désilles, MD

Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis

The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% …

18 years of age All Phase N/A

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

years of age All Phase N/A
P Professor Deb Pal

Biology of Juvenile Myoclonic Epilepsy

The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to …

10 - 40 years of age All Phase N/A
M Mariana Mirabel, MD, PhD

Cardio-Oncology Registry

Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias. CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt. The objectives …

18 years of age All Phase N/A
S Sylvie Lang, PhD

Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation

The aim of the present prospective study is to further develop and validate a composite risk score predicting both ischemic and bleeding risk, based on epidemiologic, clinical, biological, and/or morphologic complementary data. First, the investigators will assess the predictive performance of current clinical risk scores. Second, the investigators will assess …

18 years of age All Phase N/A
B Boston Scientific Clinical Research

Patient Retrospective Outcomes (PRO)

This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.

18 years of age All Phase N/A
M Mounira Kharoubi

Registre HEAR, Healthcare European Amyloidosis Registry

This is a non-interventional, prospective, retrospective, non-comparative, multi-center study. In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed. The data collection will be limited to the data related to the management of the patients included throughout their follow-up. This study is …

years of age All Phase N/A
M Mariana Atencio

Biomarker Research in Inherited Movement Disorders

Inherited movement disorders are rare conditions, whose cumulative prevalence are in the order of 5-10/100,000 inhabitants, in most cases progressive and can lead to a significant loss of autonomy after one or more decades of evolution. They include spinocerebellar ataxias and hyperkinetic disorders (dystonias, choreas, tremor, parkinsonism and myoclonus with …

7 years of age All Phase N/A

Simplify language using AI